About
ProSciento provides scientific and operational expertise in the design and management of all facets of clinical development for NASH, diabetes, obesity, and related metabolic drug and device studies.
Recommended Materials
Articles
Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide
Articles
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2
Articles
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males
Related Solutions
Our Services
